A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer: A study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer

Annals of Oncology

Volumn 18, Issue 12, 2007, Pages 2000-2005

  Becouarn Y ^a   Senesse, P ^b   Thezenas S ^b   Boucher, E ^c   Adenis, A ^d   Cany, L ^e   Jacob, J H ^f   Cvitkovic, F ^g   Montoto Grillot, C ^h   Ychou, M ^b  

^a INSTITUT BERGONIÉ   (France)

^b CENTRE VAL D AURELLE   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e Clinique Francheville   (France)

^f CENTRE FRANÇOIS BACLESSE   (France)

^g CENTRE RENÉ HUGUENIN   (France)

^h Centres de Lutte Contre le Cancer   (France)

Author keywords

Advanced colorectal cancer; First line treatment; FU; Irinotecan; Oxaliplatin

Indexed keywords

ALKALINE PHOSPHATASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 37349079304     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm379     Document Type: Article

References (27)

1. Bouvier AM, Remontet L, Jougla E et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 2004; 28: 877-881.
2. Colonna M, Hedelin G, Esteve J et al. National cancer prevalence estimation in France. Int J Cancer 2000; 87: 301-304.
3. Becouam Y, Brunet R, Ravaud A et al. Chimiotherapie systemique des adenocarcinomes colorectaux metastatiques. Gastroenterol Clin Biol 1992; 16: 166-176.
4. Advanced Cobrectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patents with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
5. de Gramont A, Bosset JF, Milan C et al. Randomized-trial comparing monthly low-dose leucavorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 15: 808-815.
6. Tournigand C, de Gramont A, Louvet C et al. A simplified bi-monthly regimen with leucavorin (LV) and 5-fluorouracil (5FU) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 1998; 17: 247a (Abstr 1052).
7. Rougier R, Van Cutsem E, Baletta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [erratum in Lancet 1998; 352: 1634). Lancet 1908; 352: 1407-1412.
8. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after flourouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
9. Andre T, Louvet C, Maindrault-Goebel F et al. CPT-11 (irinotecan) addition. to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic-colorectal cancer. GERCOR. Eur J Cancer, 1999; 95; 1343-1347.
10. Douillard JY, Cunningham D, Rath AD et al. Irinotetan combined wtth fluorouracil compared with fluorouracil along as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial [erratum in Lancet 2000; 355: 1372]. Lancet 2000; 355: 1041-1047.
11. Saltz LB, Cox N, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
12. Becouarn Y, Rougier P. Clinical efficacy at oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 1998; 25 (Suppi 5): 23-31.
13. André T, Bensmaine MA, Louvet C et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucavorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560-3568.
14. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
15. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topolsomerase I inhibitor SN-38 and the diamino-cyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999; 5: 1189-1196.
16. Rothenberg ML, McKinney J, Hande KR et al. A Phase I Clinical and Pharmacokinetic Trial of Oxaliplatin and Irinotecan Given Every Two Weeks to Patients with Refractory Solid Tumors. ACR-NCI-EORTC International Conference, Washington, USA 1999; 18: 125 (abstr).
17. Wasserman E, Cuvier C, Loklec F et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999; 17: 1751-1759.
18. Kemeny N, Tong W, Stockman J et al. Phase I trial of weekly oxaliplatin and irinotecan in previously treated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 245a (Absr 948).
19. Goldwasser F, Gross-Goupil M, Tigaud JM et al. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Ann Oncol 2000; 11: 1463-1470.
20. Schetthauer W, Kornek GV, Raderer M et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucavorin-pretreated colorectal cancer. J Clin Oncol 1999; 117: 902-906.
21. Becouarn Y, Gamelin E, Coudert B et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplalin and irinotecan in fluorouracil-pretreated metastatic colorectal cabeer patients. J Clin Oncoll 2001; 19: 4195-4201.
22. Rougier P, Lepille D. Bennouna J et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: A randomised, multicentre phase II study. Ann Oncol 2002; 13: 1558-1567.
23. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
24. Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCT, NIH, DHHS. March 31, 2003; http://ctep.cancer.gov (9 August 2006 date last accessed).
25. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
26. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
27. Schalhom A, Fischer von Weikersthal L, Quietzch D et al. Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-□J/ folinic acid (FOLFIRI) as first-line treatment of metastatocolorectal cancer (CRC): The FIRE-Trial. Proc Am Soc Clin Oncol 2005; 24: 250s (Abstr 3516).